Our
Board
Executive Chairman Paul Rennie leads Paradigm’s team of Directors, providing guidance and oversight across the company’s activities to deliver shareholder value over the long term.
Cognisant of the fact that some of medicine’s greatest opportunities may never have come to light due to the limitations of the technology of the time, the critical eye of the Paradigm board is invaluable in the company quest to discover the true potential of molecules historically taken for granted.
Mr Rennie is recognised as a leading authority in drug development and has been involved in a number of pre-clinical and clinical trial programs over his accomplished career. He was the inaugural COO of Mesoblast and most recently as Executive VP, New Product Development at Mesoblast Ltd. Mr. Rennie has extensive experience in commercialising Intellectual Property.
Mr Rennie is recognised as a leading authority in drug development and has been involved in a number of pre-clinical and clinical trial programs over his accomplished career. He was the inaugural COO of Mesoblast and most recently as Executive VP, New Product Development at Mesoblast Ltd. Mr. Rennie has extensive experience in commercialising Intellectual Property.
Dr. Skerrett, has more than 30 years’ experience in transfusion medicine, cellular therapy, and regenerative medicine. She was the CMO of Mesoblast, a stem cell development company (2011-2019), Dir. Transfusion Medicine & Cellular Therapy at Weill Cornell Medical Center, NY (2004-2011), and Ass. Dir. Transfusion Medicine at Columbia University’s NY-Presbyterian Hospital. She has chaired the NY State Governor’s Council on Blood and Transfusion Service and served on the Board of Directors of the Fox Chase Cancer Center. She currently serves in an advisory role on the Board of Visitors for the Lewis Katz School of Medicine of Temple University.
Dr. Skerrett, has more than 30 years’ experience in transfusion medicine, cellular therapy, and regenerative medicine. She was the CMO of Mesoblast, a stem cell development company (2011-2019), Dir. Transfusion Medicine & Cellular Therapy at Weill Cornell Medical Center, NY (2004-2011), and Ass. Dir. Transfusion Medicine at Columbia University’s NY-Presbyterian Hospital. She has chaired the NY State Governor’s Council on Blood and Transfusion Service and served on the Board of Directors of the Fox Chase Cancer Center. She currently serves in an advisory role on the Board of Visitors for the Lewis Katz School of Medicine of Temple University.
Amos Meltzer is a scientist and an intellectual property lawyer with over 25
years of experience in international trade and in commercialising technologies
principally in the life sciences sector. He has presided over life science
research and product development projects clinical trials as well as the
commercialisation of life sciences assets through both licensing and the sale
and marketing of a pharmaceutical product. Previously Amos has served as in
house counsel and IP director at two Nasdaq-listed companies Cgen and Gilat,
as a non-executive director of a biotechnology company Evogene and as VP
of Business Development and then CEO of an ASX-listed biopharmaceutical
company Immuron. Amos currently serves as Chief Operating Officer of neuro-
medical device company Synchron, chairman of the board of surgeons’
education services company Vasculab and as a legal advisor to a number of
ASX listed and private life science companies.
Amos Meltzer is a scientist & IP lawyer with over 25 years of experience in international trade and commercialising technologies, principally in the life sciences sector. He has presided over research & product development projects clinical trials as well as the commercialisation of assets through licensing and the sale & marketing of a pharmaceutical product. Previously Amos has served as in-house counsel & IP director at two Nasdaq-listed companies, as a non-executive director of a biotechnology company & as CEO of an ASX-listed biopharma company. Amos currently serves as CEO of neuro-medical device company Synchron, chairman of the board of surgeons’ education services company, Vasculab and as a legal advisor to a number of ASX listed & private life science companies.
Matthew joins the Paradigm board with more than 25 years in business creation, strategy, and expansion in healthcare and medical diagnostics globally. He is currently the CEO, Managing Director and Founder of AM Diagnostics Pty Ltd, a manufacturer and distributor of world class medical diagnostic products.
Matthew has significant experience with global regulatory agencies, in particular the Australian TGA and US FDA. Through his role as Founder and CEO of AM Diagnostics, Matthew drove the company’s expansion into the United States in 2009 and is a leading biotechnology device supplier with a deep understanding of sales channels in both the US medical wholesale market and retail market, and how to negotiate with private health providers.
Matthew joins the Paradigm board with more than 25 years in business creation, strategy, and expansion in healthcare and medical diagnostics globally. He is currently the CEO, Managing Director and Founder of AM Diagnostics Pty Ltd, a manufacturer and distributor of world class medical diagnostic products.
Matthew has significant experience with global regulatory agencies, in particular the Australian TGA and US FDA. Through his role as Founder and CEO of AM Diagnostics, Matthew drove the company’s expansion into the United States in 2009 and is a leading biotechnology device supplier with a deep understanding of sales channels in both the US medical wholesale market and retail market, and how to negotiate with private health providers.
Our
Board
Executive Chairman Paul Rennie leads Paradigm’s team of Directors, providing guidance and oversight across the company’s activities to deliver shareholder value over the long term.
Cognisant of the fact that some of medicine’s greatest opportunities may never have come to light due to the limitations of the technology of the time, the critical eye of the Paradigm board is invaluable in the company quest to discover the true potential of molecules historically taken for granted.
Mr Rennie is recognised as a leading authority in drug development and has been involved in a number of pre-clinical and clinical trial programs over his accomplished career. He was the inaugural COO of Mesoblast and most recently as Executive VP, New Product Development at Mesoblast Ltd. Mr. Rennie has extensive experience in commercialising Intellectual Property.
Mr Rennie is recognised as a leading authority in drug development and has been involved in a number of pre-clinical and clinical trial programs over his accomplished career. He was the inaugural COO of Mesoblast and most recently as Executive VP, New Product Development at Mesoblast Ltd. Mr. Rennie has extensive experience in commercialising Intellectual Property.
Dr. Skerrett, has more than 30 years’ experience in transfusion medicine, cellular therapy, and regenerative medicine. She was the CMO of Mesoblast, a stem cell development company (2011-2019), Dir. Transfusion Medicine & Cellular Therapy at Weill Cornell Medical Center, NY (2004-2011), and Ass. Dir. Transfusion Medicine at Columbia University’s NY-Presbyterian Hospital. She has chaired the NY State Governor’s Council on Blood and Transfusion Service and served on the Board of Directors of the Fox Chase Cancer Center. She currently serves in an advisory role on the Board of Visitors for the Lewis Katz School of Medicine of Temple University.
Dr. Skerrett, has more than 30 years’ experience in transfusion medicine, cellular therapy, and regenerative medicine. She was the CMO of Mesoblast, a stem cell development company (2011-2019), Dir. Transfusion Medicine & Cellular Therapy at Weill Cornell Medical Center, NY (2004-2011), and Ass. Dir. Transfusion Medicine at Columbia University’s NY-Presbyterian Hospital. She has chaired the NY State Governor’s Council on Blood and Transfusion Service and served on the Board of Directors of the Fox Chase Cancer Center. She currently serves in an advisory role on the Board of Visitors for the Lewis Katz School of Medicine of Temple University.
Amos Meltzer is a scientist and an intellectual property lawyer with over 25
years of experience in international trade and in commercialising technologies
principally in the life sciences sector. He has presided over life science
research and product development projects clinical trials as well as the
commercialisation of life sciences assets through both licensing and the sale
and marketing of a pharmaceutical product. Previously Amos has served as in
house counsel and IP director at two Nasdaq-listed companies Cgen and Gilat,
as a non-executive director of a biotechnology company Evogene and as VP
of Business Development and then CEO of an ASX-listed biopharmaceutical
company Immuron. Amos currently serves as Chief Operating Officer of neuro-
medical device company Synchron, chairman of the board of surgeons’
education services company Vasculab and as a legal advisor to a number of
ASX listed and private life science companies.
Amos Meltzer is a scientist & IP lawyer with over 25 years of experience in international trade and commercialising technologies, principally in the life sciences sector. He has presided over research & product development projects clinical trials as well as the commercialisation of assets through licensing and the sale & marketing of a pharmaceutical product. Previously Amos has served as in-house counsel & IP director at two Nasdaq-listed companies, as a non-executive director of a biotechnology company & as CEO of an ASX-listed biopharma company. Amos currently serves as CEO of neuro-medical device company Synchron, chairman of the board of surgeons’ education services company, Vasculab and as a legal advisor to a number of ASX listed & private life science companies.
Matthew joins the Paradigm board with more than 25 years in business creation, strategy, and expansion in healthcare and medical diagnostics globally. He is currently the CEO, Managing Director and Founder of AM Diagnostics Pty Ltd, a manufacturer and distributor of world class medical diagnostic products.
Matthew has significant experience with global regulatory agencies, in particular the Australian TGA and US FDA. Through his role as Founder and CEO of AM Diagnostics, Matthew drove the company’s expansion into the United States in 2009 and is a leading biotechnology device supplier with a deep understanding of sales channels in both the US medical wholesale market and retail market, and how to negotiate with private health providers.
Matthew joins the Paradigm board with more than 25 years in business creation, strategy, and expansion in healthcare and medical diagnostics globally. He is currently the CEO, Managing Director and Founder of AM Diagnostics Pty Ltd, a manufacturer and distributor of world class medical diagnostic products.
Matthew has significant experience with global regulatory agencies, in particular the Australian TGA and US FDA. Through his role as Founder and CEO of AM Diagnostics, Matthew drove the company’s expansion into the United States in 2009 and is a leading biotechnology device supplier with a deep understanding of sales channels in both the US medical wholesale market and retail market, and how to negotiate with private health providers.
